Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma talks about Be R/Ready, a resource for patients with relapsed or refractory acute myeloid leukemia (AML) and their physicians. 

AML is a rare aggressive cancer of the blood and bone marrow with a low 5-year survival rate. Relapsed and refractory AML are common. According to Dr. Krivoshik, approximately one-third of AML patients may have mutations on the FLT3 gene and knowledge of that may help guide treatment options. 

Be R/Ready is a resource meant to educate patients and healthcare providers about the importance of genetic testing for patients with relapsed and refractory AML and encourage patient-physician communication.

For more information about AML and other rare cancers, visit